-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Masitinib in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Masitinib in Asthma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Masitinib in Asthma Drug Details: Masitinib (AB-1010) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Masitinib in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Masitinib in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Masitinib in Peritoneal Cancer Drug Details: Masitinib (AB-1010) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imatinib in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib in Pulmonary Arterial Hypertension Drug Details: Imatinib (AER-901) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OpSCF in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OpSCF in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OpSCF in Atopic Dermatitis (Atopic Eczema) Drug Details: Monoclonal antibodies...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMS-088 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMS-088 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMS-088 in Refractory Acute Myeloid Leukemia Drug Details: NMS-088...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMS-088 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMS-088 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMS-088 in Relapsed Acute Myeloid Leukemia Drug Details: NMS-088...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imatinib Mesylate in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib Mesylate in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib Mesylate in Pulmonary Arterial Hypertension Drug Details: Imatinib mesylate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (MG-010 + Sorafenib) in Non-Small Cell Lung Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (MG-010 + Sorafenib) in Non-Small Cell Lung Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (MG-010 + Sorafenib) in Non-Small Cell Lung Carcinoma...
-
Sector Analysis
Business of the Tennis Grand Slams 2024 – Property Profile, Sponsorship and Media Landscape
Reasons to buy the ‘Business of the Tennis Grand Slams’ report: Analyze the four major tennis grand slams with a clear breakdown of the commercial revenue generated. Assess the main sponsorship rights at the slams and get a clear breakdown of the brands involved in the sport. Examine the biggest deals of each grand slam and insightful ideal analysis in terms of industry and brand location. Assess the main kit suppliers in the Tennis Grand Slams, covering the top 32...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sitravatinib Malate in Metastatic Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Metastatic Uveal Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sitravatinib Malate in Metastatic Uveal Melanoma Drug Details: Sitravatinib...